J4T0 logo

Onconetix DB:J4T0 Stock Report

Last Price

€2.82

Market Cap

€2.8m

7D

0%

1Y

-58.3%

Updated

21 Dec, 2024

Data

Company Financials

J4T0 Stock Overview

A biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology. More details

J4T0 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Onconetix, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Onconetix
Historical stock prices
Current Share PriceUS$2.82
52 Week HighUS$10.66
52 Week LowUS$2.74
Beta3.25
1 Month Change0%
3 Month Change-27.32%
1 Year Change-58.33%
3 Year Changen/a
5 Year Changen/a
Change since IPO-99.85%

Recent News & Updates

Recent updates

Shareholder Returns

J4T0DE BiotechsDE Market
7D0%-0.8%-1.6%
1Y-58.3%-13.0%6.8%

Return vs Industry: J4T0 underperformed the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: J4T0 underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is J4T0's price volatile compared to industry and market?
J4T0 volatility
J4T0 Average Weekly Movementn/a
Biotechs Industry Average Movement6.9%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: J4T0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine J4T0's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
201812Ralph Schiessonconetix.gcs-web.com

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.

Onconetix, Inc. Fundamentals Summary

How do Onconetix's earnings and revenue compare to its market cap?
J4T0 fundamental statistics
Market cap€2.76m
Earnings (TTM)-€49.46m
Revenue (TTM)€1.79m

1.5x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
J4T0 income statement (TTM)
RevenueUS$1.87m
Cost of RevenueUS$2.60m
Gross Profit-US$732.03k
Other ExpensesUS$50.87m
Earnings-US$51.60m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-6.22
Gross Margin-39.13%
Net Profit Margin-2,758.66%
Debt/Equity Ratio24.3%

How did J4T0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 18:06
End of Day Share Price 2024/09/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Onconetix, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vernon BernardinoH.C. Wainwright & Co.
Jason McCarthyMaxim Group